Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
Public ClinicalTrials.gov record NCT06028074. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation With Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects With Advanced Solid Malignancies
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Study identification
- NCT ID
- NCT06028074
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 111 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 11, 2023
- Primary completion
- Aug 31, 2026
- Completion
- Nov 30, 2026
- Last update posted
- Aug 16, 2026
2023 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Angeles Clinic and Research Institute | Los Angeles | California | 90025 | Recruiting |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| UCLA Hematology/Oncology | Los Angeles | California | 90095 | Recruiting |
| UCSF Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94143 | Recruiting |
| Florida Cancer Specialists | Sarasota | Florida | 34232 | Recruiting |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | Recruiting |
| Rutgers Cancer Institute of NJ | New Brunswick | New Jersey | 08903 | Recruiting |
| Tennessee Oncology, PLLC | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - Baylor Sammons Cancer Center | Dallas | Texas | 75246 | Recruiting |
| NEXT Oncology Dallas | Irving | Texas | 75039 | Recruiting |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06028074, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 16, 2026 · Synced Sep 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06028074 live on ClinicalTrials.gov.